Project: Development of a novel allosteric modulator to treat post-traumatic stress disorder
Acronym | DiSARM FEAR (Reference Number: 113468) |
Duration | 15/10/2019 - 17/10/2022 |
Project Topic | The consortium will deliver DiSARM FEAR, a novel clinical candidate for Post-Traumatic Stress Disorder (PTSD), by developing small-molecule negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 7 (mGluR7) to reduce fear memory reconsolidation. We will generate a lead and perform pharmacology, ADME/PK, non-GLP toxicity and efficacy studies in new PTSD models. After the project, DiSARM FEAR will complete preclinical development and enter clinical trials. |
Network | Eurostars 2 |
Call | Eurostars Cut–off 11 |